Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04600505 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol
A Phase 1 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT04600505 is a Phase 1 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by AstraZeneca. The registered enrollment target is 47 participants, below the 650-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04600505, a Phase 1 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will evaluate bioavailability, pharmacokinetics, safety, and tolerability of budesonide, glycopyrronium and formoterol (BGF) metered dose inhaler (MDI) formulated with 3 different propellants: Propellant 1 (Treatment A \[test\]), Propellant 2 (Treatment B \[test\]) and Hydrofluoroalkane (HFA) (Treatment C \[reference\]).
Conditions Studied
Interventions
- DRUG Treatment A
- DRUG Treatment B
- DRUG Treatment C
Study Locations (1)
California
- Research Site - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2021-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04600505
The ClinicalTrials.gov registry entry for NCT04600505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 650-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (93% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 3 interventions - of which Treatment A is the first listed.
NCT04600505 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04600505 about?
NCT04600505 is a clinical study titled "A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol". The study will evaluate bioavailability, pharmacokinetics, safety, and tolerability of budesonide, glycopyrronium and formoterol (BGF) metered dose inhaler (MDI) formulated with 3 different propellants: Propellant 1 (Treatment A \[test\]), Propellant 2 (Treatment B \[test\]) and Hydrofluoroalkane (H...
What is the current status of trial NCT04600505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2020-10-19. Estimated completion is 2021-05-17.
What conditions does trial NCT04600505 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT04600505?
The interventions under investigation include: Treatment A (DRUG), Treatment B (DRUG), Treatment C (DRUG).
Who is sponsoring clinical trial NCT04600505?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04600505 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
Effectiveness of the WearME System for COPD Severity and Respiratory Function
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.